Departments of Surgery.
Research.
Ann Surg. 2023 Oct 1;278(4):e812-e819. doi: 10.1097/SLA.0000000000005790. Epub 2023 Jan 3.
The use and impact of antibiotics and the impact of causative pathogens on clinical outcomes in a large real-world cohort covering the entire clinical spectrum of necrotizing pancreatitis remain unknown.
International guidelines recommend broad-spectrum antibiotics in patients with suspected infected necrotizing pancreatitis. This recommendation is not based on high-level evidence and clinical effects are unknown.
This study is a post-hoc analysis of a nationwide prospective cohort of 401 patients with necrotizing pancreatitis in 15 Dutch centers (2010-2019). Across the patient population from the time of admission to 6 months postadmission, multivariable regression analyses were used to analyze (1) microbiological cultures and (2) antibiotic use.
Antibiotics were started in 321/401 patients (80%) administered at a median of 5 days (P25-P75: 1-13) after admission. The median duration of antibiotics was 27 days (P25-P75: 15-48). In 221/321 patients (69%) infection was not proven by cultures at the time of initiation of antibiotics. Empirical antibiotics for infected necrosis provided insufficient coverage in 64/128 patients (50%) with a pancreatic culture. Prolonged antibiotic therapy was associated with Enterococcus infection (OR 1.08 [95% CI 1.03-1.16], P =0.01). Enterococcus infection was associated with new/persistent organ failure (OR 3.08 [95% CI 1.35-7.29], P <0.01) and mortality (OR 5.78 [95% CI 1.46-38.73], P =0.03). Yeast was found in 30/147 cultures (20%).
In this nationwide study of patients with necrotizing pancreatitis, the vast majority received antibiotics, typically administered early in the disease course and without a proven infection. Empirical antibiotics were inappropriate based on pancreatic cultures in half the patients. Future clinical research and practice must consider antibiotic selective pressure due to prolonged therapy and coverage of Enterococcus and yeast. Improved guidelines on antimicrobial diagnostics and therapy could reduce inappropriate antibiotic use and improve clinical outcomes.
在涵盖坏死性胰腺炎整个临床谱的大型真实世界队列中,抗生素的使用和影响以及病原体对临床结果的影响尚不清楚。
国际指南建议对疑似感染性坏死性胰腺炎患者使用广谱抗生素。这一建议没有基于高级别的证据,其临床效果也尚不清楚。
这是一项对荷兰 15 个中心的 401 例坏死性胰腺炎患者进行的全国前瞻性队列的事后分析(2010-2019 年)。在患者入院至入院后 6 个月的整个时间内,使用多变量回归分析(1)微生物培养和(2)抗生素使用情况。
321/401 例(80%)患者开始使用抗生素,中位时间为入院后 5 天(P25-P75:1-13)。抗生素的中位疗程为 27 天(P25-P75:15-48)。在 221/321 例(69%)患者中,在开始使用抗生素时,培养物并未证实存在感染。在 128 例(50%)胰腺培养阳性的感染性坏死患者中,经验性抗生素治疗对肠球菌感染的覆盖不足。延长抗生素治疗与肠球菌感染相关(OR 1.08 [95% CI 1.03-1.16],P =0.01)。肠球菌感染与新发/持续器官衰竭(OR 3.08 [95% CI 1.35-7.29],P <0.01)和死亡率(OR 5.78 [95% CI 1.46-38.73],P =0.03)相关。在 147 例培养物中发现了 30 例(20%)酵母菌。
在这项针对坏死性胰腺炎患者的全国性研究中,绝大多数患者接受了抗生素治疗,通常在疾病早期使用,且没有明确的感染。根据胰腺培养结果,有一半的患者使用的经验性抗生素是不恰当的。由于治疗时间延长和肠球菌及酵母的覆盖,未来的临床研究和实践必须考虑抗生素的选择压力。改进抗菌药物诊断和治疗指南可以减少不适当的抗生素使用并改善临床结果。